Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04392232 · ClinicalTrials.gov registry record · Phase 2
A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection
A Phase 2 study of COVID-19 and Coronavirus, sponsored by TriHealth.
- Completed
- Registry status
- Phase 2
- Development phase
- 159
- Enrollment target
- 2
- Study locations
NCT04392232 is a Phase 2 study of COVID-19 and Coronavirus that has completed, run by TriHealth. The registered enrollment target is 159 participants, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT04392232, a Phase 2 study of COVID-19 and Coronavirus, has completed, sponsored by TriHealth.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 159 participants
- Enrollment target
- 2
- Study locations
Study Summary
Purpose of Study • The purpose of this study to evaluate, the effectiveness of convalescent plasma in combatting the symptoms and effects of the coronavirus disease, COVID-19. Beyond supportive care, there are no proven treatment options for COVID-19.
Conditions Studied
Interventions
- DRUG Convalescent Plasma
Study Locations (2)
Ohio
- Good Samaritan Hospital - Cincinnati
- Bethesda North Hospital - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2020-05-05 |
| Est. Completion | 2021-09-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04392232
The ClinicalTrials.gov registry entry for NCT04392232 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 159 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The listed sponsor is TriHealth, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which Convalescent Plasma is the first listed.
NCT04392232 reports 2 study locations spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT04392232 about?
NCT04392232 is a clinical study titled "A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection". Purpose of Study • The purpose of this study to evaluate, the effectiveness of convalescent plasma in combatting the symptoms and effects of the coronavirus disease, COVID-19. Beyond supportive care, there are no proven treatment options for COVID-19.
What is the current status of trial NCT04392232?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 159 participants. The study started on 2020-05-05. Estimated completion is 2021-09-21.
What conditions does trial NCT04392232 study?
This clinical trial studies the following conditions: COVID-19, Coronavirus, Convalescent Plasma.
What interventions are being tested in trial NCT04392232?
The interventions under investigation include: Convalescent Plasma (DRUG).
Who is sponsoring clinical trial NCT04392232?
This trial is sponsored by TriHealth, which has 81 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04392232 being conducted?
This trial has 2 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
A Nasal Treatment for COVID-19
RECRUITING · Phase 2
-
Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults
RECRUITING · Phase 2
-
Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19
RECRUITING · Phase 2
-
Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.